Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Summary

Sunitinib is a novel small molecule receptor tyrosine kinase inhibitor with direct antitumor effects as well as antiangiogenetic activity. Preclinical and clinical data for Sunitinib and data about angiogenesis and growth regulation in melanoma suggest the activity of Sunitinib in melanoma. This study will investigate the efficacy, safety and tolerability of Sunitinib as palliative treatment in chemo-refractory metastatic melanoma.

Timeline

Start

2009-03

Primary completion

2013-05

Completion

2013-05

Outcome

Outcome not reported

Stopped (Enrollment): “slow recruitment”

Drugs

Indications